Fei Jia, Doctor of Clinical Medicine at Jinan University, Postdoctoral Fellow at The First Military Medical University, and Visiting Scholar at Memorial Sloan-Kettering Cancer Center, USA. Here is the English translation of the additional sentence:Currently, he is a Professor in the Department of Biochemistry, School of Basic Medical Sciences, Jinan University, and the Director of the Guangdong Provincial Engineering Technology Research Center for Small Nucleic Acid Drug Development.

Main research directions : 1. Mechanisms of non-coding RNAs in tumors and identification of novel drug targets.2. Development and industrialization of small nucleic acid drugs and mRNA drugs.3. Organoid research on bone marrow and leukemia, and targeted therapy for leukemia.4. Discovery of molecular glue mechanisms of active ingredients from traditional Chinese medicine and research on anti-tumor drug resistance.

Representative academic achievements：.

Fei Jia received the Second Prize for Technological Invention of the Outstanding Scientific Research Achievement Award in Higher Education Institutions (Science and Technology) from the Ministry of Education in 2022, as well as two Third Prizes for Technological Invention of the Guangdong Provincial Science and Technology Award. As the lead inventor, he has been granted 15 national invention patents. He is the lead editor of the academic monographs Development Technology of Small Nucleic Acid Drugs and Development Technology and Industrialization of Small Nucleic Acid Drugs,

Representative publications in the past five years are as follows:

1. Berberine, a natural molecular glue, overcomes CML resistance via TRIM28-mediated HIF1α ubiquitination and subsequent PDE4D-dependent ferroptosis. Cell Reports 2026（accepted）. (IF=6.9,  A1-1 Top , corresponding  author）

2.Small RNA activation of CDH13 expression overcome BCR-ABL1-independent imatinib-resistance and their signaling pathway studies in chronic myeloid leukemia. Cell Death Dis. 2024 Aug 23;15(8):615. (IF=9.6,  A1-1。Top , corresponding  author）

3.Single-cell resolution reveals RalA GTPase expanding hematopoietic stem cells and facilitating of BCR-ABL1-driven leukemogenesis in a CRISPR/Cas9 gene editing mouse model.International. Int J Biol Sci. 2023; 19(4): 1211-1227.（IF=10.75,  A1-2, corresponding  author）

4.Discovery of berberine that targetedly induce autophagic degradation of both BCR-ABL and T315I BCR-ABL through recruiting LRSAM1 for overcoming imatinib-resistance. Clin Cancer Res. 2020 Aug 1; 26(15):4040-4053.（SCI, IF= 12.531, A1-1, corresponding  author）

5.The identification of Long non-coding RNA H19 target and its function in Chronic myeloid leukemia (CML). Mol Ther-Nucleic Acids. 2020 Mar 6;19:1368-1378（SCI, IF 8.886, A1-2区, corresponding  author）

Email：tfeijia@jnu.edu.cn